Navigation Links
Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
Date:9/5/2007

ohnson & Johnson Pharmaceutical Research & Development. L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is part of Johnson & Johnson, the world's most broad-based producer of healthcare products. J&JPRD is headquartered in Raritan, New Jersey (USA), and has facilities throughout Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.

About Ortho Biotech Products, L.P.

Ortho Biotech Products, L.P. is a leading biopharmaceutical company devoted to helping improve the lives of patients with cancer and with anemia due to multiple causes, including chronic kidney disease. Since it was founded in 1990, Ortho Biotech and its worldwide affiliates have earned a global reputation for researching, manufacturing and marketing innovative products that enhance patients' health. Located in Bridgewater, N.J., Ortho Biotech is an established market leader in Epoetin alfa therapy for anemia management. The company also markets treatments for recurrent ovarian cancer, rejection of transplanted organs and other serious illnesses. For more information, visit http://www.orthobiotech.com.


'/>"/>
SOURCE Ortho Biotech Products, L.P.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
7. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Roper Industries Completes the Acquisition of Verathon, Inc. 2Roper Industries Completes the Acquisition of Verathon, Inc. 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 2Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 3Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 4Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 5Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 2Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 3Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 4Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 5Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 6Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 7Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 8Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 9Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 10Reportlinker Adds Ambulatory and Bathroom Aids - A Worldwide Market Review 11Octapharma Aims to Expand U S Immune Globulin Therapy Portfolio 14224 1Octapharma Aims to Expand U S Immune Globulin Therapy Portfolio 14224 2Octapharma Aims to Expand U S Immune Globulin Therapy Portfolio 14224 3Oxygen Biotherapeutics Inc Receives Phase II Trial Approval in Israel 5033 1Oxygen Biotherapeutics Inc Receives Phase II Trial Approval in Israel 5033 2Discovery could improve hepatitis C treatment 58129 1Discovery could improve hepatitis C treatment 58129 2